BioRestorative Therapies, Inc.
BRTX
$1.75
$0.02031.17%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 401.00K | 377.00K | 174.10K | 149.50K | 145.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 401.00K | 377.00K | 174.10K | 149.50K | 145.80K |
| Cost of Revenue | 28.00K | 24.70K | 6.50K | -- | -- |
| Gross Profit | 373.00K | 352.30K | 167.60K | 149.50K | 145.80K |
| SG&A Expenses | 6.60M | 7.68M | 8.82M | 9.84M | 11.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.96M | 12.46M | 13.08M | 13.70M | 15.37M |
| Operating Income | -11.56M | -12.09M | -12.90M | -13.55M | -15.22M |
| Income Before Tax | -8.98M | -9.65M | -3.79M | -5.47M | -10.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.98 | -9.65 | -3.79 | -5.47 | -10.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.98M | -9.65M | -3.79M | -5.47M | -10.42M |
| EBIT | -11.56M | -12.09M | -12.90M | -13.55M | -15.22M |
| EBITDA | -11.37M | -11.90M | -12.73M | -13.38M | -15.06M |
| EPS Basic | -1.17 | -1.46 | -0.28 | -1.25 | -2.85 |
| Normalized Basic EPS | -0.60 | -0.91 | -0.17 | -0.78 | -1.78 |
| EPS Diluted | -1.17 | -1.46 | -0.93 | -1.90 | -3.50 |
| Normalized Diluted EPS | -0.60 | -0.91 | -0.58 | -1.19 | -2.19 |
| Average Basic Shares Outstanding | 31.04M | 27.60M | 24.05M | 19.82M | 16.86M |
| Average Diluted Shares Outstanding | 31.04M | 27.60M | 31.81M | 27.57M | 24.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |